申请人:Molecular Insight Pharmaceuticals, Inc.
公开号:US20160346410A1
公开(公告)日:2016-12-01
Compounds according to Formula I and Formula II are potent inhibitors of PSMA.
Pharmaceutical compositions may include a complex of a radionuclide and a Formula I compound or a Formula II compound. Methods include using the radionuclide complex of a Formula I compound or a Formula II compound for treating or diagnosis of a disease or a condition associated with PSMA activity.